Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

This randomized trial compared rituximab with cyclophosphamide followed by azathioprine in severe ANCA-associated vasculitis. This noninferiority trial showed that there was no difference at 18 months for the induction and maintenance of remissions between groups. : Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
Source: Nephrology Now - Category: Urology & Nephrology Authors: Tags: Clinical Nephrology Clinical Trial Results Glomerulonephritis Vasculitis Source Type: research